VCT220
Sources
registry, as of 2026-09-16Stale
https://clinicaltrials.gov/study/NCT06939296
A Research Study of VCT220 in Adult Chinese Participants With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 840. Conditions Obesity; Overweight. The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once da
ClinicalTrials.gov NCT06939296 protocol and results modules
registry, as of 2025-07-01Stale
https://clinicaltrials.gov/study/NCT06569355
A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population. Overall status COMPLETED. Phases PHASE2. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 250. Conditions Obesity; Overweight. The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo
ClinicalTrials.gov NCT06569355 protocol and results modules
registry, as of 2026-09-21Stale
https://clinicaltrials.gov/study/NCT07360275
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 160. Conditions Hypertension. The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
ClinicalTrials.gov NCT07360275 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07349381
A Food-Effect Study of CX11 in Healthy Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 32. Conditions Obesity & Overweight; Type 2 Diabetes. This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants
ClinicalTrials.gov NCT07349381 protocol and results modules
registry, as of 2026-03-31Stale
https://clinicaltrials.gov/study/NCT07056842
This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole. Overall status COMPLETED. Phases PHASE1. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 32. Conditions Obesity &Amp; Overweight. This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite VCT289. Cohort 1 will assess the impact of rifampin
ClinicalTrials.gov NCT07056842 protocol and results modules
registry, as of 2026-03-31Stale
https://clinicaltrials.gov/study/NCT07065058
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 24. Conditions Obesity &Amp; Overweight. This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the pharmacokinetics and safety of repaglinide , rosuvastatin, and di
ClinicalTrials.gov NCT07065058 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06939296
Each participant will take the study drug orally once daily for 12 months. VCT220 A small molecule GLP-1R drug, film coated tablet Placebo Placebo tablets
NCT06939296 description or intervention text